What's trending

5 most popular innovation stories in Houston this week

From movers and shakers headed to Austin for MassChallenge to a Q&A with a sports tech founder, here are this week's trending stories. Shobeir Ansari/Getty Images

Houston companies have been up to some huge accomplishments, from winning money at Texas A&M University to launching a local software-focused venture capital fund. Here's what big news trended this week in Houston innovation.

Need more than just trending news on Fridays? Subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.

These are the Houston companies headed to MassChallenge Texas in Austin

A handful of Houston startups will be bouncing back and forth to Austin for the second annual MassChallenge Texas accelerator. Getty Images

It's the second cohort for Boston-based MassChallenge Texas in Austin, and this year's 74 selected finalists are well represented by Houston. Here are seven of the Houston-related companies that will be trekking back and forth to Austin from June until October.

3 Houston innovators to know this week

From health care to politics, here's who you need to know in Houston innovation this week. Courtesy photos

There's no summer slowdown in sight, as Houston's innovation world keeps turning. Texas Children's Hospital is amping up their attention to innovation — and so is the mayor. Meanwhile, a local software company just made a big hire. Read about what innovators you need to keep an eye on.

Houston companies take home big prizes from a Texas A&M startup competition

Spark Biomedical took home first place at the Texas A&M New Ventures Competition. Courtesy of Texas A&M

Earlier this month, 16 startups competed in the 2019 Texas A&M New Ventures Competition for more than $350,000 in cash and in-kind services — the largest pool of prizes in the contest's history.

Houston had a huge presence at TNVC this year. Several Houston startups competed in the technology- and science-focused pitch competition, and the top three prizes were claimed by Houstonians. Of the 13 health and life science companies that were named semifinalists, seven were related to the TMC Innovation Institute. Check out the Houston companies that walked away from the TNVC with cash and/or prizes.the Houston companies that walked away from the TNVC with cash and/or prizes.

This Houston sports tech entrepreneur wants more big wins for Houston

Stephane Smith wants his company, Integrated Bionics, and its sports tech sensor to be a big win for Houston. Courtesy of Integrated Bionics

It took Stephane Smith and his brother, Yves, a few tries to get a revolutionary sports device that the market actually wanted. Now that they have, their Houston-based company, Integrated Bionics, has its Titan Sensor device being used worldwide — from Zimbabwe and Israel to Brazil and Mexico.

The Titan, which launched in 2017, syncs GPS with video and provides athletic metrics at an attainable price. Most of the company's customers are soccer teams primarily in the collegiate space — with some professional and even youth teams. Smith says the company has a firm footing within soccer because that's where this technology really started. Read more about the Titan Sensor and its creator.

Houston startup consulting firm launches $20 million venture capital fund for early stage software companies

The new, Houston-based GSTVC fund will dole out $20 million to scalable SaaS companies. Photo by rawpixel.com from Pexels

A new venture capital fund has launched in Houston to serve seed-stage, software-as-a-service companies. The $20 million fund plans to make its first investment by the end of the third quarter of this year.

The fund is launching under Golden Section Technology, a Houston-based software consulting firm focused on demystifying technology and providing training and counseling for entrepreneurs. Managing director, Dougal Cameron, says he and a small group of investors made investments in some of the companies that GST has worked with over the years. Learn more about this new fund.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News